blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2663574

EP2663574 - INHIBITORS OF RETROVIRAL REPLICATION [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  27.11.2015
Database last updated on 03.09.2024
Most recent event   Tooltip27.11.2015Application deemed to be withdrawnpublished on 30.12.2015  [2015/53]
Applicant(s)For all designated states
The Scripps Research Institute
10550 North Torrey Pines Road
La Jolla, CA 92037 / US
[2013/47]
Inventor(s)01 / VALENTE, Susana
265 Cardinal Trail
Stuart FL 34997 / US
02 / BARAN, Phil, S.
5160 Great Meadow Drive
San Diego CA 92130 / US
 [2013/47]
Representative(s)Hutter, Anton, et al
Venner Shipley LLP
5 Stirling House
Stirling Road The Surrey Research Park
Guildford GU2 7RF / GB
[N/P]
Former [2013/47]Hutter, Anton, et al
Venner Shipley LLP
200 Aldersgate
London EC1A 4HD / GB
Application number, filing date12734207.910.01.2012
WO2012US20741
Priority number, dateUS201161431198P10.01.2011         Original published format: US 201161431198 P
[2013/47]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2012096934
Date:19.07.2012
Language:EN
[2012/29]
Type: A2 Application without search report 
No.:EP2663574
Date:20.11.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 19.07.2012 takes the place of the publication of the European patent application.
[2013/47]
Search report(s)International search report - published on:US26.10.2012
(Supplementary) European search report - dispatched on:EP18.11.2014
ClassificationIPC:C07J71/00, C07D273/00, C07D319/00, C07D321/00, C07D401/00
[2013/47]
CPC:
A61K31/4709 (EP,US); A61K31/4725 (EP,US); A61K31/58 (EP,US);
A61K45/06 (US); C07D405/04 (EP,US); C07D495/04 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/47]
TitleGerman:RETROVIREN-REPLIKATIONSHEMMER[2013/47]
English:INHIBITORS OF RETROVIRAL REPLICATION[2013/47]
French:INHIBITEURS DE RÉPLICATION RÉTROVIRALE[2013/47]
Entry into regional phase24.07.2013National basic fee paid 
24.07.2013Search fee paid 
24.07.2013Designation fee(s) paid 
24.07.2013Examination fee paid 
Examination procedure24.07.2013Amendment by applicant (claims and/or description)
24.07.2013Examination requested  [2013/47]
16.06.2015Application deemed to be withdrawn, date of legal effect  [2015/53]
12.08.2015Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2015/53]
Fees paidRenewal fee
21.01.2014Renewal fee patent year 03
Penalty fee
Additional fee for renewal fee
31.01.201504   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]EP0911393  (TAKEDA CHEMICAL INDUSTRIES LTD [JP]) [X] 1-3,14,15 * Agents having "Corticostatin" activity and precursors thereof, for use in the treatment of HIV and other viral infections: see par.1, 4, 6, 10, 11(8) "corticostatin" and see page 23, line 18; page 26, line 37: treatment of "AIDS virus infection" *;
 [Y]  - BABA M ET AL, "Anti-angiogenesis agent DS-4152 is a potent and selective inhibitor of HIV-1 replication in vitro.", AIDS (LONDON, ENGLAND) JAN 1994, (199401), vol. 8, no. 1, ISSN 0269-9370, pages 43 - 48, XP002731842 [Y] 1-15 * DS-4152, a potent angiogenesis inhibitor is an inhibitor of HIV. *

DOI:   http://dx.doi.org/10.1097/00002030-199401000-00007
 [Y]  - AOKI SHUNJI ET AL, "Cortistatins A, B, C, and D, anti-angiogenic steroidal alkaloids, from the marine sponge Corticium simplex.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 15 MAR 2006, (20060315), vol. 128, no. 10, ISSN 0002-7863, pages 3148 - 3149, XP002731843 [Y] 1-15 * Cortistatins are anti-angiogenic agents: see abstract, results and discussion *

DOI:   http://dx.doi.org/10.1021/JA057404H
 [Y]  - AOKI SHUNJI ET AL, "Structure-activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids.", BIOORGANIC & MEDICINAL CHEMISTRY 1 NOV 2007, (20071101), vol. 15, no. 21, ISSN 0968-0896, pages 6758 - 6762, XP002731844 [Y] 1-15 * Cortistatins are anti-angiogenic agents: see abstract, results and discussion *

DOI:   http://dx.doi.org/10.1016/J.BMC.2007.08.017
 [T]  - GUILLAUME MOUSSEAU ET AL, "An Analog of the Natural Steroidal Alkaloid Cortistatin A Potently Suppresses Tat-Dependent HIV Transcription", CELL HOST & MICROBE, ELSEVIER, NL, vol. 12, no. 1, doi:10.1016/J.CHOM.2012.05.016, ISSN 1931-3128, (20120514), pages 97 - 108, (20120626), XP028432327 [T] * See the entire document: disclosure of the invention *

DOI:   http://dx.doi.org/10.1016/j.chom.2012.05.016
International search[X]US6365787  (HUANG ET AL);
 [Y]WO2009137335  ;
 [A]WO2010024930  (NATHANSON ET AL);
 [T]US2012071477  (PORTER ET AL)
 [Y]  - TOSCHI ET AL., "HIV-1 Tat Regulates Endothelial Cell Cycle Progression via Activation of the Ras/ERK MAPK Signaling Pathway", MOLECULAR BIOLOGY OF THE CELL, vol. 17, no. 4, (20060125), pages 1985 - 1994, URL: http://www.molbiolcell.org/contenUl7/4/1985.full.pdf, (20120713), XP055119584

DOI:   http://dx.doi.org/10.1091/mbc.E05-08-0717
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.